| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Depatuxizumab Basic information |
| Product Name: | Depatuxizumab | | Synonyms: | Depatuxizumab;Research Grade Depatuxizumab (DHB86908);Research Grade Depatuxizumab;Depatuxizumab (anti-EGFR) | | CAS: | 1471999-69-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Depatuxizumab Structure]() |
| | Depatuxizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Depatuxizumab Usage And Synthesis |
| Uses | Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer[1]. | | in vivo | Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth significantly in U87MGde2-7 glioblastoma multiforme (GBM) models and A431 squamous xenograft models of Nu/Nu mice[1].
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth and pEGFR levels in EGFRvIII-positive GBM SN0199 PDX models of NSG mice[1].
Depatuxizumab (2-40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth with dose dependent manner in SCC15 xenograft models of SCID Beige mice[1].
| Animal Model: | U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1] | | Dosage: | 10, 40 mg/kg, three times a week for 2 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited tumor growth significantly more than Cetuximab (HY-P9905).
Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
|
| Animal Model: | EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1] | | Dosage: | 10, 40 mg/kg, three times a week for 2 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited tumor growth significantly and reduced levels of pEGFR.
|
| Animal Model: | A431 squamous xenograft model of Nu/Nu mice[1] | | Dosage: | 10, 40 mg/kg, three times a week for 2 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg.
Inhibited tumor growth by 58% at 40 mg/kg.
|
| Animal Model: | SCC15 xenograft model of SCID Beige mice[1] | | Dosage: | 2, 10, 20, 40 mg/kg, three times a week for 2 weeks | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Inhibited tumor growth with dose manner.
Reduced the level of pEGFR and total EGFR in time-dependent.
Reduced cell proliferation as measured by phospho-histone H3.
Increased apoptosis as measured by caspase-3 cleavage.
Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
|
| | References | [1] Reilly EB, et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. DOI:10.1158/1535-7163.MCT-14-0820 |
| | Depatuxizumab Preparation Products And Raw materials |
|